Press Release's - Most Recent

Press Release's - All

• Symbol: LLBO
• Common Stock
• Shares Authorized: 4,950,000,000
• Par Value:   $ .00001
• Issued & Outstanding: 2,966,700,000
• Float: 2,818,400,000
• Number of Shareholders: 9,000-9500 (approx)
• Stock Quote - Click here
• Investor FAQs – Click here

The Company’s product, the First Warning System™, is in the process of preparing for a 510(k) submission to the FDA. If a 510(k) is approved, commercialization of the the First Warning System™ could continue to be pursued. However, there can be no assurance that the FDA will approve the Company’s submission. There is a possibility that the FDA could reject the technology and the claims concerning the capabilities of the First Warning System™. The claims to be included in the submission are expected to cover the First Warning System’s process and ability to identify breast tissue abnormalities, which may indicate cancerous or precancerous conditions.

The FDA could require the Company to conduct the testing of additional patients to validate the capabilities and claims of the First Warning System™. Should additional patient testing be required, additional financing resources could, and most likely would, be necessary. There is no assurance that the Company could acquire the funding required to conduct additional patient testing.

Should the FDA clear the First Warning System‘s claims and technology as included in the 510(k) submission, there can be no assurance that the targeted markets, physicians and their patients, will adopt the process in sufficient quantities to create a commercially profitable venture, hence, impacting the companies potential future value.

This, the Lifeline BiotechnologiesTM (www.lbti.com) website contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In particular, when used in this website, the words “believe,” “expects,” “intends,” “will,” “anticipates,” “anticipated,” or “may,” and similar conditional expressions are intended to identify forward-looking statements within the meaning of the Act and are subject to the safe harbor created by the Act. Except for historical information, all of the statements, expectations and assumptions contained in this website are forward-looking that involve a number of risks and uncertainties, including, but not limited to, certain delays beyond the Company’s control with respect to market acceptance of new technologies or products; delays in testing and evaluation of products; FDA clearance; business conditions and the amount of growth in the Company’s industry and general economy; competitive factors; ability to attract and retain personnel; the ability to attract and obtain adequate financing; the price of the Company’s stock; and other factors and risks. The Company takes no obligation to update or correct forward-looking statements or information on this website.